Payment overview · 2025
General Payments
$758.47
3 reported records · 3 companies
Healthcare provider profile · identity verified
Jason Margolesky, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · MIAMI, FL · NPI 1801162813
Verified facts
What the public records show
CMS Open Payments records show Jason Margolesky, MD received $758.47 in general payments during 2025 across 3 reported records.
Eton Pharmaceuticals, Inc. accounted for 65.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Crexont.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Linzess by this doctor in 2024.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREXONT as an associated drug or biological on 11358 records involving 3581 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Crexont by this doctor in 2024.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RYTARY as an associated drug or biological on 200 records involving 121 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Rytary by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Eton Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $500.00 | 65.9% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $134.97 | 17.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $123.50 | 16.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $500.00 | 1 |
| Food and Beverage | $258.47 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BETAINE ANHYDROUS Normalized: betaine anhydrous |
Drug | Eton Pharmaceuticals, Inc. | $500.00 | 1 | 2025 |
Source payment records
|
|||||
| CARGLUMIC ACID Normalized: carglumic acid |
Drug | Eton Pharmaceuticals, Inc. | $500.00 | 1 | 2025 |
Source payment records
|
|||||
| GALZIN Normalized: galzin |
Drug | Eton Pharmaceuticals, Inc. | $500.00 | 1 | 2025 |
Source payment records
|
|||||
| NITISINONE Normalized: nitisinone |
Drug | Eton Pharmaceuticals, Inc. | $500.00 | 1 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $134.97 | 1 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $123.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREXONT crexont |
2025 | Crexont | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | CREXONT open payments reported associated product |
CMS Open Payments — General Payments 11358 supporting records · 3581 recipient NPIs · example record 1220525531 |
Crexont · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | RYTARY open payments reported associated product |
CMS Open Payments — General Payments 200 supporting records · 121 recipient NPIs · example record 1220526035 |
Rytary · 2024 Exact normalized brand match · 1 Part D row |
126 | 28 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Carbidopa-Levodopa | Carbidopa/Levodopa | 306 | 107 |
| Rytary | Carbidopa/Levodopa | 126 | 28 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 102 | 27 |
| Clonazepam | Clonazepam | 93 | 25 |
| Gocovri | Amantadine Hcl | 91 | 15 |
| Rivastigmine | Rivastigmine Tartrate | 83 | 25 |
| Rasagiline Mesylate | Rasagiline Mesylate | 67 | 18 |
| Trazodone Hcl | Trazodone Hcl | 65 | 22 |
| Amantadine | Amantadine Hcl | 64 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 60 | 19 |
| Neupro | Rotigotine | 45 | suppressed |
| Gabapentin | Gabapentin | 42 | 14 |
| Mirtazapine | Mirtazapine | 40 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 39 | 12 |
| Alprazolam | Alprazolam | 38 | suppressed |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 37 | 14 |
| Ropinirole Er | Ropinirole Hcl | 34 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 32 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 30 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 29 | 11 |
| Donepezil Hcl | Donepezil Hcl | 27 | 12 |
| Memantine Hcl | Memantine Hcl | 27 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 27 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 26 | 11 |
| Primidone | Primidone | 22 | suppressed |
| Inbrija | Levodopa | 21 | suppressed |
| Rivastigmine | Rivastigmine | 21 | suppressed |
| Nourianz | Istradefylline | 19 | suppressed |
| Xadago | Safinamide Mesylate | 19 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 18 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 18 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 16 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Acetazolamide | Acetazolamide | 12 | suppressed |
| Crexont | Carbidopa/Levodopa | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $758.47 · 3 records | Eton Pharmaceuticals, Inc. | BETAINE ANHYDROUS, CARGLUMIC ACID, CREXONT, GALZIN, NITISINONE, VYALEV | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Crexont play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error